Startup profile · funding coverage
Braveheart funding, valuation and investors
Late-clinical biotech developing HCM therapy BHB-1893 (Hengrui-partnered).
Keep track of Braveheart
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A
$185M · November 2025
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$185M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a
Investors in latest funding
Other: Andreessen Horowitz
Overview
Braveheart Bio is a biotechnology company developing BHB-1893, a late-clinical-stage therapy for hypertrophic cardiomyopathy (HCM), in partnership with Hengrui Pharmaceuticals. In November 2025 Braveheart launched with a $185M Series A financing with participation from Andreessen Horowitz Bio + Health, Forbion, OrbiMed, Frazier Life Sciences, and Enavate Sciences. The company targets a large cardiovascular indication where several competitors pursue overlapping mechanisms. a16z's stake was notable enough to appear in public filing discussions around ownership percentages.
Why Braveheart is interesting
Crossover launch with $185M Series A for hypertrophic cardiomyopathy — a16z Bio + Health holds ~14% per IPO filing context; crowded cardio metabolic market.
Product & use cases
Clinical-stage biotech advancing BHB-1893 for HCM — partnered with Hengrui on development and commercial rights structure.
- Hypertrophic cardiomyopathy treatment development
- Late-clinical asset advancement toward registration trials
- Cardiovascular franchise build via partnered molecule
Key facts
- Launch (Nov 2025): $185M Series A with a16z Bio + Health (Braveheart press)
- Asset: BHB-1893 for HCM; Hengrui partnership
- Co-investors: Forbion, OrbiMed, Frazier Life Sciences, Enavate Sciences
Funding history (newest first)
Series A
2025-11 $185MSource: https://www.braveheart.bio/news/braveheart-bio-launches
Investors in our directory
Funds linked from Braveheart's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Large launch round and Hengrui partnership vs. smaller single-asset biotechs; a16z and crossover syndicate validation.
HCM became hot biotech territory after MyoKardia's success. Braveheart enters with partnered asset and $185M war chest. Clinical differentiation vs. aficamten and others will determine outcome — early stage with high execution risk typical of cardio metabolic biotech.
-
Cytokinetics (aficamten) direct
HCM drug development competitor in same indication.
-
Bristol Myers / MyoKardia legacy programs incumbent
Established cardio pharma with HCM interest.
-
Other HCM biotech entrants direct
Crowded HCM pipeline post-MyoKardia acquisition.
Notable stories
- Braveheart launched publicly in November 2025 with one of larger biotech Series A rounds of the year.
- a16z ownership ~14% cited in IPO filing context per directory research notes.
Industries
Related funding articles
Venture Capital Tracker pieces that cover Braveheart's financing or category context.
FAQs about Braveheart
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.